Litcius/Paper detail

Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis

Roberto Rossotti, Giovanna Travi, Nicola Ughi, Matteo Corradin, Chiara Baiguera, Roberto Fumagalli, Maurizio Bottiroli, Michele Mondino, Marco Merli, Andrea Bellone, Andriano Basile, Ruggero Ruggeri, Fabrizio Colombo, Mauro Moreno, Stefano Pastori, Carlo Federico Perno, Paolo Tarsia, Oscar Massimiliano Epis, Massimo Puoti

2020Journal of Infection129 citationsDOIOpen Access PDF

Topics & Concepts

TocilizumabMedicineInternal medicineComorbidityProportional hazards modelSurvival analysisAdverse effectRetrospective cohort studyDiseaseCOVID-19 Clinical Research StudiesPsoriasis: Treatment and PathogenesisSARS-CoV-2 and COVID-19 Research
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis | Litcius